Literature DB >> 8187339

Profiles of immunoregulatory cytokine production in vitro in patients with IgA nephropathy and their kindred.

V Scivittaro1, L Gesualdo, E Ranieri, C Marfella, S A Schewn, S N Emancipator, F P Schena.   

Abstract

We hypothesized that the altered immunoglobulin synthesis and/or lymphocyte function apparent in patients with IgA nephropathy (IgAN) is due to a primary defect in lymphokine regulation. In addition, we reasoned that such changes in lymphokine production might be, at least partially, genetically determined. To assess the extent of lymphocyte abnormalities, we investigated the profile of cytokine production from peripheral blood mononuclear cells (PBMC) in 34 IgAN patients and 44 of their first degree relatives, 10 of whom had persistent microhaematuria. Compared with healthy volunteers (n = 34), PBMC from patients showed increased IL-2 production both spontaneously or after phytohaemagglutinin (PHA) (20 micrograms/ml) stimulation, whereas IL-4 and interferon-gamma (IFN-gamma) production were significantly higher only after stimulation. Microhaematuric relatives had a similar pattern of cytokine production, whereas non-microhaematuric relatives showed no significant difference versus normals. The altered pattern of cytokine production appeared to be quite specific to IgAN patients and their microhaematuric relatives, because patients with other forms of primary glomerulonephritis (n = 17) did not differ from normal individuals. Patients and relatives that hyperproduced IL-4 were also hyperproducers of IL-2. No such congruence was seen in any other group or with any other pairing of cytokines. We propose that a subpopulation of IgAN patients bear lymphocytes intrinsically hyperresponsive. Among those individuals such hyperresponsiveness may be causally related to the pathogenesis and/or character of IgAN.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187339      PMCID: PMC1534876          DOI: 10.1111/j.1365-2249.1994.tb06559.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Incidence of IgA-related nephritides in American Indians in New Mexico.

Authors:  S M Smith; K S Tung
Journal:  Hum Pathol       Date:  1985-02       Impact factor: 3.466

2.  T-cell function.

Authors:  H Sakai
Journal:  Contrib Nephrol       Date:  1984       Impact factor: 1.580

3.  Low incidence of IgA nephropathy in blacks.

Authors:  J C Jennette; S D Wall; A S Wilkman
Journal:  Kidney Int       Date:  1985-12       Impact factor: 10.612

4.  IgA synthesis by lymphocytes from patients with IgA nephropathy and their relatives.

Authors:  F B Waldo; L Beischel; C D West
Journal:  Kidney Int       Date:  1986-06       Impact factor: 10.612

5.  Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy.

Authors:  F P Schena; V Scivittaro; E Ranieri; R Sinico; S Benuzzi; M Di Cillo; L Aventaggiato
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

6.  IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis.

Authors:  A R Clarkson; A E Seymour; A J Thompson; W D Haynes; Y L Chan; B Jackson
Journal:  Clin Nephrol       Date:  1977-11       Impact factor: 0.975

7.  The role of mesangial complement in the hematuria of experimental IgA nephropathy.

Authors:  S N Emancipator; Z Ovary; M E Lamm
Journal:  Lab Invest       Date:  1987-09       Impact factor: 5.662

8.  Familial IgA nephropathy. Evidence of an inherited mechanism of disease.

Authors:  B A Julian; P A Quiggins; J S Thompson; S Y Woodford; K Gleason; R J Wyatt
Journal:  N Engl J Med       Date:  1985-01-24       Impact factor: 91.245

9.  Immunological abnormalities in healthy relatives of patients with IgA nephropathy.

Authors:  J Egido; R A Blasco; J Sancho; L Hernando
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

10.  Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients.

Authors:  G D'Amico; E Imbasciati; G Barbiano Di Belgioioso; S Bertoli; G Fogazzi; F Ferrario; G Fellin; A Ragni; G Colasanti; L Minetti
Journal:  Medicine (Baltimore)       Date:  1985-01       Impact factor: 1.889

View more
  7 in total

1.  T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation.

Authors:  S R Chintalacharuvu; N U Nagy; N Sigmund; J G Nedrud; M E Amm; S N Emancipator
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  For further investigations in IgA nephropathy the approach from phenotype to genotype is welcome.

Authors:  F P Schena
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 3.  Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.

Authors:  Krzysztof Kiryluk; Jan Novak; Ali G Gharavi
Journal:  Annu Rev Med       Date:  2012-10-16       Impact factor: 13.739

4.  Increased IL-10 production by stimulated whole blood cultures in primary IgA nephropathy.

Authors:  J W De Fijter; M R Daha; W E Schroeijers; L A van Es; C Van Kooten
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

5.  B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement.

Authors:  Alfred Hj Kim; Jun-Jae Chung; Shreeram Akilesh; Ania Koziell; Sanjay Jain; Jeffrey B Hodgin; Mark J Miller; Thaddeus S Stappenbeck; Jeffrey H Miner; Andrey S Shaw
Journal:  JCI Insight       Date:  2017-11-02

6.  Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1.

Authors:  Koshi Yamada; Noriyoshi Kobayashi; Tomomi Ikeda; Yusuke Suzuki; Toshinao Tsuge; Satoshi Horikoshi; Steven N Emancipator; Yasuhiko Tomino
Journal:  Nephrol Dial Transplant       Date:  2010-06-15       Impact factor: 5.992

7.  T cell cytokine polarity as a determinant of immunoglobulin A (IgA) glycosylation and the severity of experimental IgA nephropathy.

Authors:  S R Chintalacharuvu; M Yamashita; N Bagheri; T G Blanchard; J G Nedrud; M E Lamm; Y Tomino; S N Emancipator
Journal:  Clin Exp Immunol       Date:  2008-07-11       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.